Apolipoprotein A‐I as a Molecular Target of the Immunomodulatory Peptide Jusvinza: Mechanistic Insights From Affinity and In Silico Studies
Journal of Peptide Science · 2026-08 · 32 (8)
DOI: 10.1002/psc.70113 ↗At a glance
Journal article in Journal of Peptide Science, published online on 2026-07-03. Written by Camila Viviana Rosales and 8 co-authors. Institution: Autoinmmunity and Inflammation Group, Biomedical Research Division, Center for Genetic Engineering and Biotechnology, Playa, La Habana, Cuba. Major MEDLINE topics: Apolipoprotein A-I, Peptides. 74 references. Funded by: Center for Genetic Engineering and Biotechnology (CIGB).
Abstract (original language)
Jusvinza is an immunomodulatory pharmaceutical drug developed for the treatment of rheumatoid arthritis. Its active ingredient is an altered peptide ligand—derived from a T‐cell epitope of the human 60‐kDa heat shock protein—referred to as CIGB‐814. Jusvinza has also proven effective in reducing hyperinflammation in COVID‐19. However, molecular targets of CIGB‐814 in patients remain undefined, and this study is aimed at identifying specific plasma proteins that interact with CIGB‐814. Affinity chromatography and mass spectrometry analysis revealed apolipoprotein A‐I as a CIGB‐814‐binding partner. Interestingly, no apolipoprotein A‐I bands were detected in the affinity matrix of the wild‐type peptide (designated as E18‐3). In this context, it was relevant to analyze how the substitution of Asp18 with Leu—used to design CIGB‐814 from the wild‐type peptide—confers its ability to bind apolipoprotein A‐I. Docking studies predicted the N‐terminal domain of apolipoprotein A‐I as the most likely region for peptide interaction and suggested a strong connection between CIGB‐814 and apolipoprotein A‐I. Further validation by molecular dynamics simulations suggests that CIGB‐814 may enhance the flexibility of structural areas in apolipoprotein A‐I critical for high‐density lipoproteins assembly. Additionally, an affinity enzyme‐linked immunosorbent assay (ELISA) confirmed that apolipoprotein A‐I has a tenfold greater affinity for CIGB‐814 compared to the wild‐type peptide. These integrated experimental and computational findings demonstrate that a single residue substitution is critical for apolipoprotein A‐I recognition. In addition, this study provides mechanistic insight into CIGB‐814 immunomodulatory and metabolic effects, expanding the therapeutic potential of Jusvinza to metabolic diseases associated with lipid homeostasis imbalance.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Autoinmmunity and Inflammation Group, Biomedical Research Division, Center for Genetic Engineering and Biotechnology, Playa, La Habana, Cuba.
- Bioinformatic Group, Biomedical Research Division, Center for Genetic Engineering and Biotechnology, Playa, La Habana, Cuba.
- Proteomic Group, Biomedical Research Division, Center for Genetic Engineering and Biotechnology, Playa, La Habana, Cuba.
- Raydel Research Institute, Medical Innovation Complex, Daegu, Republic of Korea.
Funding
- Center for Genetic Engineering and Biotechnology (CIGB)
Cite
APA
Rosales, C. V., Cedeño, M. H., Chinea, G., Besada, V., Ramos, Y., Cho, K. H., González, L. J., Donato, G. M., & Del Carmen Domínguez-Horta, M. (2026). Apolipoprotein A‐I as a Molecular Target of the Immunomodulatory Peptide Jusvinza: Mechanistic Insights From Affinity and In Silico Studies. Journal of Peptide Science, 32(8). https://doi.org/10.1002/psc.70113
Vancouver
Rosales CV, Cedeño MH, Chinea G, Besada V, Ramos Y, Cho KH, et al. Apolipoprotein A‐I as a Molecular Target of the Immunomodulatory Peptide Jusvinza: Mechanistic Insights From Affinity and In Silico Studies. Journal of Peptide Science. 2026;32(8). doi:10.1002/psc.70113
BibTeX
@article{Rosales2026,
author = {Rosales, Camila Viviana and Cedeño, Mabel Hernández and Chinea, Glay and Besada, Vladimir and Ramos, Yassel and Cho, Kyung-Hyun and González, Luis Javier and Donato, Gillian Martínez and Del Carmen Domínguez-Horta, María},
title = {Apolipoprotein A‐I as a Molecular Target of the Immunomodulatory Peptide Jusvinza: Mechanistic Insights From Affinity and In Silico Studies},
journal = {Journal of Peptide Science},
year = {2026},
volume = {32},
number = {8},
doi = {10.1002/psc.70113}
}
EUVIMED